子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 四环化合物 | CN201080025574.4 | 2010-06-09 | CN102459172B | 2015-06-24 | 木下和大; 麻生康辅; 古市纪之; 伊藤俊也; 河田发夫; 石井畅也; 坂本洋; 洪右上; 朴敃廷; 小野芳幸; 加藤泰晴; 森上贤治; 江村岳; 及川信宏 |
| 本发明提供一种含有ALK抑制化合物且能有效治疗和预防伴随有ALK异常的疾病，例如癌、癌转移、抑郁症或认知功能障碍的治疗和预防药。上述课题，通过含有下列通式(I)所示的化合物、其盐或者它们的溶剂化物的医药组合物来实现，其中，式中的标记，参考说明书中的定义。 | ||||||
| 2 | 用于有机电致发光器件的材料 | CN201080022810.7 | 2010-05-03 | CN102448946A | 2012-05-09 | 克里斯托夫·普夫卢姆; 阿尔内·比辛; 埃米尔·侯赛因·帕勒姆; 特雷莎·穆希卡-费尔瑙德; 霍尔格·海尔; 菲利普·施特塞尔 |
| 本发明描述了具有电子和空穴传输性能的茚并咔唑衍生物，所述茚并咔唑衍生物特别是用于电致发光器件的发光层和/或电荷传输层中或用作基质材料。本发明还提供了制备本发明化合物的方法和包括它们的电子器件。 | ||||||
| 3 | 高传导率钙-活化K通道开启剂 | CN02808370.9 | 2002-04-15 | CN100540538C | 2009-09-16 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙-活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N-R4，O或S，R1与R2各自独立地表示氢，卤素，羧基，氨基，低级烷基，低级烷氧羰基，低级链烯基，环-低级烷基，氨基甲酰基，芳基，杂环基或杂环基-取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 4 | 用于有机电致发光器件的材料 | CN201510574449.3 | 2010-05-03 | CN105218525A | 2016-01-06 | 克里斯托夫·普夫卢姆; 阿尔内·比辛; 埃米尔·侯赛因·帕勒姆; 特雷莎·穆希卡-费尔瑙德; 霍尔格·海尔; 菲利普·施特塞尔 |
| 本发明涉及用于有机电致发光器件的材料。具体地，本发明描述了具有电子和空穴传输性能的茚并咔唑衍生物，所述茚并咔唑衍生物特别是用于电致发光器件的发光层和/或电荷传输层中或用作基质材料。本发明还提供了制备本发明化合物的方法和包括它们的电子器件。 | ||||||
| 5 | 用于有机电致发光器件的材料 | CN201080022810.7 | 2010-05-03 | CN102448946B | 2015-10-21 | 克里斯托夫·普夫卢姆; 阿尔内·比辛; 埃米尔·侯赛因·帕勒姆; 特雷莎·穆希卡-费尔瑙德; 霍尔格·海尔; 菲利普·施特塞尔 |
| 本发明描述了具有电子和空穴传输性能的茚并咔唑衍生物，所述茚并咔唑衍生物特别是用于电致发光器件的发光层和/或电荷传输层中或用作基质材料。本发明还提供了制备本发明化合物的方法和包括它们的电子器件。 | ||||||
| 6 | 四环化合物 | CN201080025574.4 | 2010-06-09 | CN102459172A | 2012-05-16 | 木下和大; 麻生康辅; 古市纪之; 伊藤俊也; 河田发夫; 石井畅也; 坂本洋; 洪右上; 朴敃廷; 小野芳幸; 加藤泰晴; 森上贤治; 江村岳; 及川信宏 |
| 本发明提供一种含有ALK抑制化合物且能有效治疗和预防伴随有ALK异常的疾病，例如癌、癌转移、抑郁症或认知功能障碍的治疗和预防药。上述课题，通过含有下列通式(I)所示的化合物、其盐或者它们的溶剂化物的医药组合物来实现，其中，式中的标记，参考说明书中的定义。 | ||||||
| 7 | 高传导率钙－活化K通道开启剂 | CN02808370.9 | 2002-04-15 | CN1503786A | 2004-06-09 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙－活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N－R4，O或S，R1与R2各自独立地表示氢，卤素，羧基，氨基，低级烷基，低级烷氧羰基，低级链烯基，环－低级烷基，氨基甲酰基，芳基，杂环基或杂环基－取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 8 | 基于4H-噻吩并[3,2-C]色烯的背板胶质乙酰酯酶抑制剂及其用法 | CN201280025844.0 | 2012-05-23 | CN103649072A | 2014-03-19 | 约瑟夫·巴博萨; 肯尼斯·戈登·卡森; 迈克尔·瓦尔特·加德彦; 贾森·帕特里克·希利; 韩强; 罗斯·玛博恩; 普拉温·帕巴; 小詹姆斯·塔弗; 克里斯滕·M·泰拉诺瓦; 阿肖克·图努里; 许小炼 |
| 本文描述了可用于抑制背板胶质乙酰酯酶的化合物，以及包含这种化合物的组合物和它们用于治疗影响骨的疾病和障碍的方法。 | ||||||
| 9 | 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类 | CN200680044705.7 | 2006-11-20 | CN101316818B | 2011-08-31 | P·耶尔; M·C·卢卡斯; R·C·舍恩菲尔德; M·维拉; R·J·韦克特 |
| 本发明提供了式(I)化合物或其药学上可接受的盐、溶剂合物或前药，在式(I)中p、Ar、R1、R2、R3、Ra、Rb、Rc、Rd和Re如文中所定义。还提供了药物组合物、使用方法和制备所述化合物的方法。 | ||||||
| 10 | 高传导率钙-活化K通道开启剂 | CN200910004656.X | 2002-04-15 | CN101519386A | 2009-09-02 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙－活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N－R4，O或S，R1与R2各自独立地表示氢，卤素，氨基，低级烷基，低级烷氧羰基，低级链烯基，环低级烷基，氨基甲酰基，芳基，杂环基或杂环基－取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 11 | 3－氨基－1－芳基丙基吲哚类和氮杂取代的吲哚类 | CN200680044705.7 | 2006-11-20 | CN101316818A | 2008-12-03 | P·耶尔; M·C·卢卡斯; R·C·舍恩菲尔德; M·维拉; R·J·韦克特 |
| 本发明提供了式(I)化合物或其药学上可接受的盐、溶剂合物或前药，在式(I)中p、Ar、R1、R2、R3、Ra、Rb、Rc、Rd和Re如文中所定义。还提供了药物组合物、使用方法和制备所述化合物的方法。 | ||||||
| 12 | 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use | US14284106 | 2014-05-21 | US09624238B2 | 2017-04-18 | Joseph Barbosa; Kenneth Gordon Carson; Michael Walter Gardyan; Jason Patrick Healy; Qiang Han; Ross Mabon; Praveen Pabba; James Tarver, Jr.; Kristen M. Terranova; Ashok Tunoori; Xiaolian Xu |
| Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone. | ||||||
| 13 | Materials for organic electroluminescent devices | US14800828 | 2015-07-16 | US09537105B2 | 2017-01-03 | Christof Pflumm; Arne Buesing; Amir Hossain Parham; Teresa Mujica-Fernaud; Holger Heil; Philipp Stoessel |
| The present invention describes indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices or as matrix material. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same. | ||||||
| 14 | TETRACYCLIC COMPOUND | US15221926 | 2016-07-28 | US20160340308A1 | 2016-11-24 | Kazutomo Kinoshita; Kohsuke ASOH; Noriyuki FURUICHI; Toshiya ITO; Hatsuo KAWADA; Nobuya ISHll; Hiroshi SAKAMOTO; WooSang HONG; MinJeong PARK; Yoshiyuki ONO; Yasuharu KATO; Kenji MORIKAMI; Takashi EMURA; Nobuhiro OIKAWA |
| A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification). | ||||||
| 15 | PHENACENE COMPOUNDS FOR ORGANIC ELECTRONICS | US14399756 | 2013-04-29 | US20150126751A1 | 2015-05-07 | Florian Doetz; Thomas Weitz; Jiao Chongjun; Hiroyoshi Noguchi; Ang Sweemeng; Mi Zhou; Doi Iori; Ashok Kumar Mishra |
| Phenacene compounds of formula (I) are disclosed. All the variables in the formula are the same as defined in the description. A thin film semiconductor comprising the above compounds, and a field effect transistor device, a photovoltaic device, an organic light emitting diode device and a unipolar or complementary circuit device comprising the thin film are also disclosed. | ||||||
| 16 | Electroactive materials | US13892468 | 2013-05-13 | US08992800B2 | 2015-03-31 | Hong Meng; Dengfu Wang |
| There is provided an electroactive material having Formula I wherein: Q is the same or different at each occurrence and can be O, S, Se, Te, NR, SO, SO2, P, PO, PO2, and SiR2; R is the same or different at each occurrence and can be hydrogen, alkyl, aryl, alkenyl, or alkynyl; R1 through R10 are the same or different and can be hydrogen, alkyl, aryl, halogen, hydroxyl, aryloxy, alkoxy, alkenyl, alkynyl, amino, alkylthio, phosphino, silyl, —COR, —COOR, —PO3R2, —OPO3R2, or CN. | ||||||
| 17 | ELECTROACTIVE MATERIALS | US13611349 | 2012-09-12 | US20130001539A1 | 2013-01-03 | HONG MENG; Dengfu Wang |
| There is provided an electroactive material having Formula I wherein: Q is the same or different at each occurrence and can be O, S, Se, Te, NR, SO, SO2, P, PO, PO2, and SiR2; R is the same or different at each occurrence and can be hydrogen, alkyl, aryl, alkenyl, or alkynyl; R1 through R10 are the same or different and can be hydrogen, alkyl, aryl, halogen, hydroxyl, aryloxy, alkoxy, alkenyl, alkynyl, amino, alkylthio, phosphino, silyl, —COR, —COOR, —PO3R2, —OPO3R2, or CN. | ||||||
| 18 | TETRACYCLIC COMPOUND | US13377300 | 2010-06-09 | US20120083488A1 | 2012-04-05 | Kazutomo Kinoshita; Kohsuke Asoh; Noriyuki Furuichi; Toshiya Ito; Hatsuo Kawada; Nobuya Ishii; Hiroshi Sakamoto; WooSang Hong; MinJeong Park; Yoshiyuki Ono; Yashuharu Kato; Kenji Morikami; Takashi Emura; Nobuhiro Oikawa |
| A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification). | ||||||
| 19 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | US12287346 | 2008-10-08 | US07803830B2 | 2010-09-28 | Pravin Iyer; Matthew C. Lucas; Ryan Craig Schoenfeld; Marzia Villa; Robert James Weikert |
| The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds. | ||||||
| 20 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | US10962881 | 2004-10-12 | US07524846B2 | 2009-04-28 | Paige Erin Mahaney |
| The present invention is directed to arylalkyl- and cycloalkylalkyl-piperazine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof. | ||||||
QQ群二维码
意见反馈
意见反馈